期刊
CELL REPORTS
卷 37, 期 5, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2021.109953
关键词
-
类别
资金
- NCI/NIH [R01CA233752]
- Ovarian Cancer Research program [W81XWH-19-1-0190 (OC180412)]
- DoD Breast Cancer Research Program (BCRP) [W81XWH-18-1-0048 (BC17097)]
The study reveals that the DR5 death receptor regulates apoptosis activation through autoinhibitory residues PPCR, providing a therapeutic strategy for potential clinical success.
Receptor clustering is the first and critical step to activate apoptosis by death receptor-5 (DR5). The recent discovery of the autoinhibitory DR5 ectodomain has challenged the long-standing view of its mechanistic activation by the natural ligand Apo2L. Because the autoinhibitory residues have remained unknown, here we characterize a crucial patch of positively charged residues (PPCR) in the highly variable domain of DR5. The PPCR electrostatically separates DR5 receptors to autoinhibit their clustering in the absence of ligand and antibody binding. Mutational substitution and antibody-mediated PPCR interference resulted in increased apoptotic cytotoxic function. A dually specific antibody that enables sustained tampering with PPCR function exceptionally enhanced DR5 clustering and apoptotic activation and distinctively improved the survival of animals bearing aggressive metastatic and recurrent tumors, whereas clinically tested DR5 antibodies without PPCR blockade function were largely ineffective. Our study provides mechanistic insights into DR5 activation and a therapeutic analytical design for potential clinical success.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据